Description
RADIOPHARMACEUTICALS FOR USE AT VASNHCS.
First action · last action
2019-10-01 · 2021-02-04
Transactions
3
First transaction's obligation
$68,000
Base + all options value (sum of deltas)
$86,837
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
—
SDVOSB flag on record
No
Parent IDV
36C26118D0081
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2019-10-01+$68,000= $68,000
- Mod P000012020-05-05+$40,000= $108,000
- Mod P000022021-02-04-$21,163= $86,837
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2019-10-01 | +$68,000 | $68,000 | RADIOPHARMACEUTICALS FOR USE AT VASNHCS. |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2020-05-05 | +$40,000 | $108,000 | RADIOPHARMACEUTICALS FOR USE AT VASNHCS. |
| Mod P00002· FUNDING ONLY ACTION | 2021-02-04 | −$21,163 | $86,837 | RADIOPHARMACEUTICALS FOR USE AT VASNHCS. |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI ULTMAJ6SMBK6)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26126P0997 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $247,204 | FY2026 |
| 36C26125N0173 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $252,379 | FY2025 |
| 36C26125D0018 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
| 36C26124N0126 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $244,300 | FY2024 |
| 36C26123N0136 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $206,116 | FY2023 |
| 36C26122N0284 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $180,655 | FY2022 |
Other recipients under 6505 from 261-NETWORK CONTRACT OFFICE 21 (36C261) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26126P1178 | OPTUM FRONTIER THERAPIES II, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,374 | FY2026 |
| 36C26126P1102 | ENVIGO RMS LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $74,586 | FY2026 |
| 36C26126P0961 | 10X GENOMICS, INC. | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $34,600 | FY2026 |
| 36C26126P1008 | OPTUM FRONTIER THERAPIES II, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,374 | FY2026 |
| 36C26126F0214 | AMICUS THERAPEUTICS US, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $22,840 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26120N0191_3600_36C26118D0081_3600 · retrieved 2026-09-26.